XORTX Therapeutics: Developing Novel Therapies That Extend Kidney Health
XORTX Therapeutics, Inc. is a drug-based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism a …
They have three programs, two of these programs are in clinical development and one is at an early stage of development, each is intended to treat rare and progressive kidney disease modulated by aberrant purine and uric acid metabolism.
XORTX Therapeutics, Inc. is a drug-based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Their focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.
They possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.
For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.
Latest Articles
.png)
Hot Companies
You might also like
Southern Silver: Is Cerro Las Minitas Emerging as a Major Silver Project?
Southern Silver is advancing its flagship Cerro Las Minitas silver-lead-zinc project in Mexico, which management describes as one of the larger, higher-grade silver-based projects globally.
CEO Clip - Southern Silver: Can a Growing Silver Resource Support a Major Underground Mine in Mexico?
Southern Silver is advancing the Cerro Las Minitas silver-lead-zinc project in Durango, Mexico, where additional drilling is being incorporated into an updated mineral resource estimate and Preliminary Economic Assessment.
